HOME >> MEDICINE >> NEWS
Other highlights in the April 21 JNCI

t density in healthy women has not been known. To investigate this, Jack Cuzick, Ph.D., of Cancer Research UK in London, and colleagues analyzed mammograms from 818 breast cancer-free women from the International Breast Cancer Intervention Study 1, a trial that tested tamoxifen's ability to prevent breast cancer in healthy women at high risk of the disease.

Treatment with tamoxifen was associated with reduced breast density, most of which occurred within the first 18 months of treatment. In women aged 45 years and younger, breast density was reduced by 13.4% on average compared with only 1.1% in women older than 55 years. The researchers hypothesize that premenopausal women experienced a larger reduction because premenopausal estrogen levels are higher and so the antiestrogenic effect of tamoxifen will be greater.

Contact: Press Office, Cancer Research UK, +44 (0) 207 061 8300, pressoffice@cancer.org.uk

Low Categories of Benign Breast Disease Still Increase Risk of Breast Cancer

There are several breast abnormalities that are not cancerous, but some of these benign conditions are associated with a greater risk of breast cancer than others. A new study has found that even women with low-category benign breast diseases are at an increased risk of breast cancer compared with women without the disease.

Jiping Wang, M.D., Ph.D., of the University of Pittsburgh, and colleagues looked at medical records for 11,307 women from the Breast Cancer Prevention Trial, 1376 of whom had the low-category benign breast disease. Women with the disease were 60% more likely than women without the disease to develop invasive breast cancer. Women with benign breast disease aged 50 years or older had a 95% increased risk of developing invasive breast cancer compared to women without benign breast disease.

Contact: Lori Garvey, National Surgical Breast and Bowel Project, (412)330-4621, <
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Apr-2004


Page: 1 2 3 4

Related medicine news :

1. Other highlights in the March 16 JNCI
2. Other highlights in the March 2 JNCI
3. Other highlights in the February 2 JNCI
4. Other highlights in the January 19 JNCI
5. Other highlights in the December 15 JNCI
6. Other highlights in the December 1 JNCI
7. Other highlights in the September 15 JNCI
8. Other highlights in the April 7 JNCI
9. Other highlights in the January 7 issue of JNCI
10. Other highlights in the December 3 issue of JNCI
11. Other highlights in the November 19 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the April JNCI

(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: